Cancel
About Albert Pan
Albert Pan is the Chief Technology Officer with over 20 years of experience in molecular simulation for scientific research and drug discovery, previously serving as a Senior Research Scientist at D.E. Shaw Research.
Known information
Albert Pan serves as the Chief Technology Officer, bringing over two decades of expertise in applying molecular simulation to address fundamental scientific questions and advance drug discovery. He spent over 12 years as a Senior Research Scientist at D.E. Shaw Research, where he led the development of free energy calculations and novel enhanced sampling methods. His work significantly contributed to fundamental biophysics research. Pan earned his Ph.D. in Chemistry from the University of California, Berkeley, and holds an A.B. in Chemistry and Physics from Harvard University, graduating magna cum laude. He was also an NIH NRSA Postdoctoral Fellow at the University of Chicago, further solidifying his credentials in the field of chemistry and biophysics.
About TandemAI
TandemAI provides an integrated drug discovery platform combining AI and physics-based tools, aimed at democratizing access to advanced drug discovery technologies. The company recently raised $35 million in Series A financing to enhance its computational and experimental capabilities.
Report inaccurate information
